Publication Name	World Journal of Gastroenterology
Manuscript ID	38855
Country	Japan

Received	2018-03-28 06:11
Peer-Review Started	2018-03-28 11:15
To Make the First Decision	2018-04-11 07:30
Return for Revision	2018-04-13 06:29
Revised	2018-04-15 02:53
Second Decision	2018-04-23 05:28
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2018-04-23 16:31
Articles in Press	2018-04-23 16:31
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-05-04 10:01
Publish the Manuscript Online	2018-05-06 13:12

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Naofumi Mukaida and Yasunari Nakamoto
ORCID	Author(s) ORCID Number Naofumi Mukaida http://orcid.org/0000-0002-4193-1851 Yasunari Nakamoto http://orcid.org/0000-0002-3160-3555
Funding Agency and Grant Number	Funding Agency Grant Number Research Programs on the Innovative Development and Application for New Drugs for Hepatitis B 17fk0310116h0001
Corresponding Author	Naofumi Mukaida, MD, PhD, Professor, Division of Molecular Bioregulation, Cancer Research Institute, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Ishikawa, Japan. mukaida@staff.kanazawa-u.ac.jp
Key Words	Natural killer T cell; Natural killer cell; Chimeric antigen receptor T cell; T cell receptor; Cytokine-induced killer cell; Program death-1; Cytotoxic lymphocyte antigen-4; Regulatory T cell; Dendritic cell; Myeloid-derived suppressor cell; PD-ligand 1; Peptide vaccine; Tumor-associated antigen; Tumor infiltrating lymphocyte
Core Tip	Hepatocellular carcinoma (HCC) develops or recurs from non-cancerous liver lesions with chronic inflammatory states and/or cirrhosis, and these lesions cannot be cured and/or eradicated by local and/or drug therapies. Immune therapy may be effective for HCC treatment by preventing non-cancerous liver lesions from progressing to HCC as well as reducing tumor burdens. However, tumor immunity is frequently depressed in tumor sites, particularly in liver microenvironment, which is prone to exhibit immune tolerance, to reduce aberrant immune responses to massively-exposed antigens via portal veins. At present, cancer immune therapy employs two distinct strategies; enhancing the effector cell functions and unleashing the immune suppressive tumor microenvironments. Here, we will summarize the current status and discuss the future perspective on immune therapy for HCC.
Publish Date	2018-05-06 13:12
Citation	Mukaida N, Nakamoto Y. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. World J Gastroenterol 2018; 24(17): 1839-1858
URL	http://www.wjgnet.com/1007-9327/full/v24/i17/1839.htm
DOI	http://dx.doi.org/10.3748/wjg.v24.i17.1839

Full Article (PDF)	WJG-24-1839.pdf
Manuscript File	38855-Review.docx
Answering Reviewers	38855-Answering reviewers.pdf
Audio Core Tip	38855-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	38855-Conflict-of-interest statement.pdf
Copyright License Agreement	38855-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	38855-Language certificate.pdf
Peer-review Report	38855-Peer-review(s).pdf
Scientific Misconduct Check	38855-Scientific misconduct check.pdf
Scientific Editor Work List	38855-Scientific editor work list.pdf